Multiple Myeloma | Topics

 
Philippe Moreau, MD, on Conclusions With VTd Plus Daratumumab in Newly Diagnosed Myeloma at ASCO 2021
July 15, 2021

Moreau discussed conclusions drawn from part 2 of the CASSIOPEIA trial and the need for further follow-up with bortezomib, thalidomide and dexamethasone plus maintenance daratumumab in newly diagnosed multiple myeloma.

Shaji Kumar, MD, Details Toxicities With Daratumumab Plus Lenalidomide/Dexamethasone in Frontline MM
July 14, 2021

At EHA 2021, Shaji Kumar, MD, reviews the toxicity profile of daratumumab plus lenalidomide and dexamethasone for patients with transplant-ineligible multiple myeloma in the first-line setting.

Subcutaneous Daratumumab Indication Expanded to Include Pomalidomide/Dexamethasone Combo for Relapsed Myeloma
July 12, 2021

The FDA approved the combination of daratumumab and hyaluronidase-fihj plus pomalidomide/dexamethasone as therapy for certain patients with pretreated multiple myeloma.